Quest Diagnostics Inc News Today

/PRNewswire/ -- The global cognitive assessment and training market size is estimated to grow by USD 39882.9 mn from 2024-2028, according to Technavio. The...

/PRNewswire/ -- The global in-vitro diagnostics market size is estimated to grow by USD 22.17 billion from 2024-2028, according to Technavio. The market is...

Quest Diagnostics Inc. and Pathai Inc. established a forward-looking deal with multiple components and room for growth. The collaboration includes Quest’s acquisition of Pathai Diagnostics – the division that provides anatomic and digital pathology laboratory services – and licensing of Pathai’s Aisight digital pathology image management system. The companies also said they may work together on development of Pathai’s algorithm products and that Quest will be a preferred provider for P...

Dublin, May 01, 2024 (GLOBE NEWSWIRE) -- The

Fitch Ratings has affirmed Quest Diagnostics, Inc.s Long-Term Issuer Default Rating , senior unsecured revolving facility and senior unsecured notes at BBB. The Rating Outlook remains...

Comprehensive SWOT Analysis: Quest Diagnostics Inc's Financial and Strategic Position

Quest Diagnostics Incorporated beats earnings expectations. Reported EPS is $2.04, expectations were $1.86.

Dublin, April 24, 2024 (GLOBE NEWSWIRE) -- The

Tuesday, Quest Diagnostics Inc DGX posted first-quarter adjusted EPS of $2.04, beating the consensus of $1.86. Sales came in at $2.37 billion, up 1.5% Y/Y,…

Quest Diagnostics Inc. expanded its Alzheimer’s disease (AD) portfolio with a blood-based biomarker test for phosphorylated tau 217 (pTau217). The test joins the company’s plasma tests for p-tau181, beta-amyloid 42/40 ratio and ApoE genetic risk as well as several cerebrospinal fluid tests for Alzheimer’s.